论文部分内容阅读
目的 :探讨拉米夫定对乙肝后活动性肝硬化的治疗效果。方法 :选择 5 4例乙肝后活动性肝硬化患者 ,单纯以拉米夫定10 0mg/d ,观察 3～ 3 6个月 ,检测血清丙氨酸氨基转移酶 (ALT) ,天冬氨酸氨基转移酶 (AST) ,总胆红素 (TBIL) ,血清白蛋白 (ALB) ,谷酰氨传酞酶 (r -GT) ,白细胞和血小板 ,eAg/eAb血清转换及HBV -DNA的阴转情况 ,B超观察肝脾及门脉情况。结果 :ALT ,AST ,ALB ,r -GT四项指标治疗后较治疗前显著改善 (P <0 .0 1,P <0 .0 5 ) ,治疗 12个月HBV -DNA阴转率为 82 .3 %。结果 :拉米夫定对乙肝后活动性肝硬化患者近期疗效显著 ,可作为治疗首选药物。
Objective: To investigate the therapeutic effect of lamivudine on active liver cirrhosis after hepatitis B Methods: Fifty-four patients with active cirrhosis after hepatitis B were enrolled in this study. The patients were randomized to receive lamivudine (100 mg / d) for 3 to 36 months. Serum levels of alanine aminotransferase (ALT), aspartate amino AST, TBIL, ALB, r-GT, leukocyte and platelet, eAg / eAb seroconversion and HBV DNA negative conversion B-observed liver and spleen and portal vein conditions. Results: The indexes of ALT, AST, ALB and r-GT were significantly improved after treatment (P <0.01, P <0.05), and the HBV-DNA negative conversion rate was 12 at 12 months. 3%. Results: Lamivudine has obvious curative effect on patients with active liver cirrhosis after hepatitis B and can be used as the drug of choice.